PDCD1 and esophageal squamous cell carcinoma: Furthermore, there is a negative correlation between the amount of MIF and the effectiveness of PD‐1 blockade immunotherapy when used in conjunction with chemotherapy as a neoadjuvant treatment for esophageal squamous cell carcinoma.61